News
Astellas said in a results update this morning that Padcev (enfortumab vedotin) will now bring in JPY 400 to 500 billion ($2.7 to $3.4 billion) on the back of the EV-302 study showing that the ...
In 2019, it got a green light for a second ADC – Padcev (enfortumab vedotin) – for metastatic urothelial cancers, adding a third in 2021 when it got FDA clearance for cervical cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback